Owing to its unprecedented efficacy based on progression-free survival, palbociclib was granted accelerated approval by the FDA in 2015 for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy in postmenopausal women [46]. Here, ERBB2 is linked to breast carcinoma.